| gepotidacin (GSK2140944) / GSK |
NCT02202187: A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers |
|
|
| Completed | 1 | 48 | US | GSK2140944, Placebo | GlaxoSmithKline | Infections, Respiratory Tract | 02/12 | 02/12 | | |
NCT02000765: A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects |
|
|
| Completed | 1 | 6 | Europe | GSK2140944 for Injection, GSK2140944 Capsule | GlaxoSmithKline | Infections, Respiratory Tract | 11/13 | 11/13 | | |
NCT01706315: This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects |
|
|
| Completed | 1 | 72 | US | GSK2140944, Placebo | GlaxoSmithKline | Infections, Respiratory Tract | 12/13 | 12/13 | | |
NCT01934205: To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944 |
|
|
| Completed | 1 | 22 | US | GSK2140944 (Single dose), GSK2140944 (Multiple dose) | GlaxoSmithKline | Infections, Bacterial | 12/13 | 12/13 | | |
NCT01615796: Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses |
|
|
| Completed | 1 | 86 | RoW | Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined, Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined | GlaxoSmithKline | Infections, Respiratory Tract | 02/14 | 02/14 | | |
NCT02045849: Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects |
|
|
| Completed | 1 | 46 | US | GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule | GlaxoSmithKline | Infections, Bacterial | 08/14 | 08/14 | | |
NCT02257398: Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers |
|
|
| Completed | 1 | 55 | US | GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo | GlaxoSmithKline | Infections, Respiratory Tract | 03/15 | 03/15 | | |
